Overview

Safety and Efficacy of Activated Recombinant Human Factor VII in Patients Undergoing Orthotopic Liver Transplantation

Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe, North America and Oceania. The aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor VII in subjects undergoing orthotopic liver transplantation surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S